Generics - Bristol-Myers Squibb


Current filters:

Bristol-Myers Squibb

Popular Filters

US Court denies appeal in Baraclude patent case

US Court denies appeal in Baraclude patent case


US pharma major Bristol-Myers Squibb yesterday announced that the US Court of Appeals for the Federal…

Anti-viralsBaracludeBristol-Myers SquibbGenericsLegalPatentsTeva Pharmaceutical IndustriesUSA

Mylan launches generic Paraplatin Injection in USA

Mylan launches generic Paraplatin Injection in USA


US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the…

Bristol-Myers SquibbGenericsMarkets & MarketingMylanOncologyParaplatinRegulationUSA

Brazil to produce atazanavir to supply SUS demand; strong pharma growth forecast for 2014


Following the Official Gazette market application filling for the drug atazanavir sulfate, an HIV protease…

Anti-viralsatazanavirBrazilBristol-Myers SquibbFiocruzGenericsMarkets & MarketingPharmaceuticalProductionSouth America

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib


The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

Teva launches generic Aprovel in UK


The UK subsidiary of Israel's Teva Pharmaceutical Industries (NYSE: TEVA), the world's largest generic…

AprovelBristol-Myers SquibbCardio-vascularEuropeGenericsMarkets & MarketingSanofiTeva Pharmaceutical Industries

Bristol-Myers anticipates significant decline in US clopidogrel sales as patent lapses


GenericsWeb, a patent analysis and search company, recently published an article based on its proprietary…

Bristol-Myers SquibbCardio-vascularClopidogrelGenericsPatentsPharmaceuticalPlavixSanofi

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis


There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Sanofi fourth-quarter in line with forecasts; collects damages


French drug major Sanofi (Euronext: SAN) this morning reported 8.8% growth in fourth-quarter 2011 sales…

ApotexBristol-Myers SquibbFinancialGenericsLegalPatentsPharmaceuticalPlavix

Company Spotlight



Back to top